The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).
Amityville, NY-The FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).
The drug-which is the generic form of ISTA Pharmaceuticals’ Bromday ophthalmic solution, 0.09%-is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Hi-Tech plans to launch the product immediately.
For more articles in this issue of Ophthalmology Times eReport, click here.
